INDUSTRY-SUPPORTED SESSIONS

​​​​​​​​​​friday, September 16, 2016

​​​​08:00-09:00 - Lomond Hall​

Neuromodulation for Cluster Headache: Why, How and When


Session Supported by ATI

Chairperson: Peter Goadsby, UK

08:00 - Update in pathophysiology of cluster headache
             Peter Goadsby, UK

08:05 - The electrical pill for cluster headache: insertion and titration
             Hans Ericson, Sweden

08:15 - Clinical e​vidence and long term results of SPG stimulation
             Mads Barløse​, Denmark

08:25 - Case Discussion
              ​Holger Kaube, Germany
              Mads Barløse​, Denmark
              Hans Ericson, Sweden

08:50 - Q&A

​08:00-09:00 - Alsh Hall

An Update on CGRP Antibodies: From Pharmacology to the Patients


Session Supported by Eli Lilly

Chairperson: Andrew Charles, USA

08:00 - Welcome and introduction
             Andrew Charles, USA

08:05 - CGRP, migraine and CGRP antibodies
             Andrew Charles, USA

08:20 - Clinical results with CGRP antibodies
             Elizabeth Leroux, Canada

08:35 - PK/PD properties of antibodies
             William Kielbasa, USA

08:45 - Panel discussion, questions and closing remarks
             Andrew​ Charles, USA
             Elizabeth Leroux, Canada
             William Kielbasa, USA

​12:45-14:15 - Lomond Hall

Breaking the status quo in the treatment of chronic migraine

allergan2.jpg

Session Supported by Allergan

Chairpersons: Manjit Matharu, UK
                       Cristina Tassorelli, Italy

12:45 - Welcome and introduction 
             Manjit Matharu, UK
             Cristina Tassorelli, Italy

12:50 - Sensory insights into the development of migraine – pain processing
             and chronification
             Anthony Dickenson, UK

13:05 - The role of BOTOX® (botulinum toxin type A) in the treatment pathway 
             Stephen Silberstein ​USA

13:20 - Improving patient’s quality of life in real-world clinical practice
             Manjit Matharu, UK

13:35 - Tailoring treatment to optimise patient outcomes 
             Andrea Negro, Italy

13:50 - Panel discussion with audience Q&A
             Moderated by: Manjit Matharu, UK
                                     Cristina Tassorelli, Italy

14:10 - Concluding thoughts
             Manjit Matharu, UK

17:45-19:15 - Lomond Hall

Investigating the CGRP pathway: Progression towards a new approach in migraine prophylaxis​


novartis100.jpg

Session Supported by Amgen/Novartis

Chairpersons: Peter GoadsbyUK
                       Lars EdvinssonSweden

17:45 - Welcome and introduction
            Peter Goadsby, UK

17:50 - How has the understanding of the CGRP receptor signalling pathway evolved?
            Lars Edvinsson, Sweden

18:00 - What are the patients’ unmet needs in migraine therapeutics?
             Messoud Ashina, Denmark

18:20 - What are the challenges involved in conducting clinical trials in migraine?
             Expert panel Introduced and moderated by:
             Gisela TerwindtThe Netherlands

18:40 What have we learne​d from anti-CGRP monoclonal antibody development to date?
             Uwe Reuter, Germany

19:00Q&A/ Closing remarks
             All Speakers
             Peter GoadsbyUK
             Lars EdvinssonSweden

saturday, september 17, 2016

​07:00-08:00 - Alsh Hall 

Migraine Medication—Friend or Foe?​

alder.jpg

Session Supported by Alder Biopharmaceuticals

07:00 - Welcome,  Introductions and Objectives

07:05Debate
            The etiological factors in migraine chronification, focusing on the role of acute
            medication vs biology, genetics, and the environment

            Julio Pascual Gómez, Spain
            Stewart J. Tepper, USA

07:45 - Bridging the divide with calcitonin gene-related peptide (CGRP) antibodies:  ALD403​
            Roger K. Cady, USA

07:55 - Closing Remarks​

​10:30-12:00 - Lomond Hall

Lasmiditan and SAMURAI Phase 3 Study Results​

colucid.jpg

Session Supported by CoLucid

Chairperson: David DodickUSA

10:30 - Welcome and Introductions
             David DodickUSA

10:40 - Lasmiditan and Trigeminal Neuronal Activity
             Peter GoadsbyUK

10:50 - In Vivo Vascular Effects of Lasmiditan in Canines and In Vitro Effects on Human
             Isolated Arteries
             Antoinette Maassen van den Brink, The Netherlands

11:00 - SAMURAI – Pivotal Phase 3 Clinical Trial
             Bernice Kuca, USA

11:35 - GLADIATOR – Open Label Phase 3 Clinical Trial
             Uwe Reuter, Germany

11:45​ - Panel Q&A – moderated
              David Dodick​, USA

12:20-14:00 - Lomond Hall

Neuromodulation of Migraine: sTMS in Clinical Practice

eneura.jpg 

Session supported by eNeura

Chairperson: Peter GoadsbyUK

12:20 - Welcome and introductions
            Peter GoadsbyUK

12:30 - Basic Principles and Clinical Applications in Migraine
             Kevin  ShieldsUK

12:55 - Mechanism of Action in Headache
             Anna AndreouUK

13:20 - Post-Market Observational US Study of Migraine (Treatment and Prevention)
             Amaal Starling, USA

13:45 - Q&A / Closing Remarks 
             Peter GoadsbyUK


Keep Me Updated